We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

The Department for Work and Pensions (DWP) is planning cuts to Personal Independence Payments (PIP) worth £5bn, according to ...

Liz Kendall, the work and pensions secretary, laid out plans for £5bn savings but faces rebellion from some Labour MPs.

Analysts have recently evaluated Ultragenyx Pharmaceutical and provided 12-month price targets. The average target is $104.8, ...

US biotech Regenxbio (Nasdaq: RGNX) has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) ...

Plus: Gene therapy with bioengineered blood cells, a possible quantum computing milestone, a new space telescope, how to not ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

MPS II Treatment and Priority Review Voucher REGENXBIO’s program for Mucopolysaccharidosis Type II (MPS II) is approaching a critical phase, with the completion of a rolling Biologics License ...

Smartleaf Asset Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 259.5% during the fourth quarter, according to its most recent filing ...

Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...

Arizona State Retirement System boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 2.4% in the 4th quarter, according to its most recent filing with the Securities ...